Leaflet: information for the user
Losartán/Hydrochlorothiazide cinfa 100 mg/12.5 mg film-coated tablets
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
Losartán/hidroclorotiazida is a combination of an angiotensin II receptor antagonist (losartán) and a diuretic (hidroclorotiazida).
The angiotensin II is a substance produced in the body that binds to receptors present in blood vessels, causing them to constrict. This results in an increase in blood pressure. Losartán prevents the binding of angiotensin II to these receptors, causing blood vessels to relax, which in turn reduces blood pressure. Hidroclorotiazida causes the kidneys to eliminate a greater amount of water and salts. This also helps to reduce blood pressure.
Losartán/hidroclorotiazida is indicated for the treatment of essential hypertension (high blood pressure).
Do not take Losartán/Hidroclorotiazida cinfa
Warnings and precautions
Consult your doctor or pharmacist before starting to take losartan/hydrochlorothiazide.
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking losartan/hydrochlorothiazide. Your doctor will decide whether to continue treatment. Do not stop taking losartan/hydrochlorothiazide on your own.
If you experience a decrease in vision or eye pain, these may be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or increased eye pressure and may occur within a few hours to a week after taking losartan/hydrochlorothiazide. If left untreated, this can lead to permanent vision loss. You may be at a higher risk of developing this if you have previously had an allergy to penicillin or sulfonamide.
Inform your doctor if you are pregnant (or if you suspect you may be). Losartan/hydrochlorothiazide is not recommended for use at the beginning of pregnancy, and it should not be taken if you are more than 3 months pregnant as it may cause serious harm to your baby when administered from that point onwards (see Pregnancy section).
It is essential to inform your doctor before taking losartan/hydrochlorothiazide:
Your doctor may monitor your kidney function, blood pressure, and electrolyte levels in your blood (e.g. potassium) at regular intervals.
See also the information under the heading “Do not take Losartán/Hidroclorotiazida cinfa”.
Other medications and Losartán/Hidroclorotiazida cinfa
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Diuretics such as hydrochlorothiazide contained in losartan/hydrochlorothiazide may interact with other medications. Preparations containing lithium should not be taken with losartan/hydrochlorothiazide without your doctor's careful monitoring. Special precautions may be necessary (e.g. blood tests) if you take potassium supplements, salt substitutes containing potassium, or potassium-sparing medications, diuretics (urine tablets), some laxatives, medications for gout, medications to control heart rhythm or diabetes (oral medications or insulin). It is also essential that your doctor knows if you are taking other medications to lower your blood pressure, steroids, cancer medications, pain medications, medications for fungal infections, or medications for arthritis, cholesterol-lowering resins such as cholestyramine, muscle relaxants, sleeping pills; opioid medications such as morphine, “pressor amines” such as adrenaline or other medications in the same group; (oral diabetes medications or insulin).
Your doctor may need to adjust your dose and/or take other precautions:
If you are taking an ACE inhibitor or aliskiren (see also the information under the headings “Do not take Losartán/Hidroclorotiazida cinfa” and “Warnings and precautions”).
Please inform your doctor when you plan to have a contrast agent with iodine.
Taking Losartán/Hidroclorotiazida cinfa with food, drinks, and alcohol
It is recommended that you do not drink alcohol while taking these tablets: alcohol and losartan/hydrochlorothiazide tablets may increase the effects of each other.
Excessive salt in the diet may counteract the effect of losartan/hydrochlorothiazide tablets.
Losartan/hydrochlorothiazide tablets can be taken with or without food.
It is recommended to avoid grapefruit juice while taking this medication.
Pregnancy, fertility, and lactation
Pregnancy
You must inform your doctor if you are pregnant (or if you suspect you may be). Your doctor will usually recommend that you stop taking losartan/hydrochlorothiazide as soon as you know you are pregnant and will recommend that you take another medication instead of losartan/hydrochlorothiazide. Losartan/hydrochlorothiazide is not recommended for use at the beginning of pregnancy, and it should not be taken if you are more than 3 months pregnant as it may cause serious harm to your baby when administered from that point onwards.
Lactation
Inform your doctor if you are breastfeeding or plan to start. Losartan/hydrochlorothiazide is not recommended for use during lactation, and your doctor will choose another treatment for you if you wish to breastfeed.
Consult your doctor or pharmacist before using any medication.
Use in children and adolescents
There is no experience with the use of losartan/hydrochlorothiazide in children. Therefore, this medication should not be administered to children.
Use in elderly patients
Losartan/hydrochlorothiazide acts with equal efficacy and is equally well tolerated by most elderly patients and young patients. Most elderly patients require the same dose as younger patients.
Driving and operating machinery
When starting treatment with this medication, you should not perform tasks that require special attention (e.g. driving a car or operating hazardous machinery) until you know how you tolerate your medication.
Losartán/Hidroclorotiazida cinfa contains lactose
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Use in athletes
This medication contains hydrochlorothiazide, which may produce a positive result in doping control tests.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Your doctor will decide the appropriate dose of losartan/hidroclorotiazide, depending on your condition and if you are taking other medications. It is essential to continue taking losartan/hidroclorotiazide as prescribed by your doctor to maintain consistent blood pressure control.
For most patients with high blood pressure, the recommended dose is 1 tablet of losartan/hidroclorotiazide 50 mg/12.5 mg per day to control blood pressure for 24 hours. It can be increased to 2 tablets of losartan/hidroclorotiazide 50 mg/12.5 mg per day or changed to 1 tablet of losartan/hidroclorotiazide 100 mg/25 mg (a higher dose) per day. The maximum daily dose is 2 tablets of 50 mg losartan/12.5 mg hidroclorotiazide per day or 1 tablet of 100 mg losartan/25 mg hidroclorotiazide per day..
If You Take More Losartán/Hidroclorotiazida cinfa Than You Should
In case of an overdose, contact your doctor immediately or go directly to the hospital for immediate medical attention.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
An overdose may cause a drop in blood pressure, palpitations, slow pulse, changes in blood composition, and dehydration..
If You Forget to Take Losartán/Hidroclorotiazida cinfa
Try to take losartan/hidroclorotiazide at the same time each day as prescribed. Do not take a double dose to compensate for missed doses. Simply return to your regular schedule.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
If you experience any of the following, stop taking the losartan/hydrochlorothiazide tablets and inform your doctor immediately or go to the emergency service of your nearest hospital:
Severe allergic reaction (skin rash, itching, swelling of the face, lips, mouth, or throat that may cause difficulty swallowing or breathing).
This is a serious but rare side effect that affects more than 1 in 10,000 patients but less than 1 in 1,000. You may need urgent medical attention or hospitalization.
The following side effects have been reported:
Frequent (may affect up to 1 in 10 people):
Infrequent (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Very rare (may affect up to 1 in 10,000 people):
Unknown frequency (cannot be estimated from available data):
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30°C.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Losartán/Hidroclorotiazida cinfa
Core: lactose monohydrate, microcrystalline cellulose, pregelatinized cornstarch and magnesium stearate.
Coating: hypromellose, titanium dioxide (E-171) and macrogol.
Appearance of the product and content of the container
Coated tablets, cylindrical with a diameter of 10.5 mm, white in color, and marked with a “L” on one face. They are presented in PVC-PE-PVDC/AL blisters. Each container contains 28 tablets.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Cinfa Laboratories, S.A
Olaz-Chipi Road, 10. Areta Industrial Estate
31620 Huarte (Navarra) – Spain
Responsible for manufacturing
Cinfa Laboratories, S.A
Olaz-Chipi Road, 10. Areta Industrial Estate
31620 Huarte (Navarra) – Spain
or
Liconsa Laboratories S.A.
Miralcampo Avenue, 7; Miralcampo Industrial Estate
19200 Azuqueca de Henares, Guadalajara (Spain)
Date of the last review of this prospectus:February 2025
The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
You can access detailed and updated information about this medicine by scanning with your smartphone the QR code included in the prospectus and packaging. You can also access this information at the following internet address:https://cima.aemps.es/cima/dochtml/p/89223/P_89223.html
QR code to:https://cima.aemps.es/cima/dochtml/p/89223/P_89223.html
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.